The concept of precision medicine as proposed by DC-ren is also of great interest to SMEs and other academic institutions. In order to allow collaborations, we established the concept of “DC-ren associated studies”. The DC-ren team was approached by Nordic Bioscience® (based in Herlev, Denmark), a company focusing amongst others on biomarkers of extracellular matrix turnover, a pathomechanism of great interest in the context of drug response and DKD progression. The DC-ren consortium and Nordic Bioscience agreed to collaborate on a project looking at the association of novel extracellular matrix turnover biomarkers with cardiorenal outcome and mortality as well as treatment response in patients with diabetes mellitus type 2.
